{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:53:15Z","timestamp":1791604395211,"version":"4.3.4"},"reference-count":47,"publisher":"BMFH Press","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.12938\/bmfh.2026-022","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T22:10:02Z","timestamp":1782339002000},"page":"264-271","source":"Crossref","is-referenced-by-count":0,"title":["<i>Bifidobacterium adolescentis<\/i> protects the intestinal barrier from obesity-related inflammatory stimuli in association with the nuclear translocation of nuclear factor kappa B"],"prefix":"10.12938","volume":"45","author":[{"given":"Tatsuya","family":"IBUKI","sequence":"first","affiliation":[{"name":"Yakult Central Institute, Yakult Honsha Co., Ltd., 5-11 Izumi, Kunitachi-shi, Tokyo 186-8650, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahide","family":"SHIGEYAMA","sequence":"additional","affiliation":[{"name":"Yakult Central Institute, Yakult Honsha Co., Ltd., 5-11 Izumi, Kunitachi-shi, Tokyo 186-8650, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moriya","family":"TSUKIMOTO","sequence":"additional","affiliation":[{"name":"Yakult Central Institute, Yakult Honsha Co., Ltd., 5-11 Izumi, Kunitachi-shi, Tokyo 186-8650, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"NAGARA","sequence":"additional","affiliation":[{"name":"Yakult Central Institute, Yakult Honsha Co., Ltd., 5-11 Izumi, Kunitachi-shi, Tokyo 186-8650, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhisa","family":"KAWAI","sequence":"additional","affiliation":[{"name":"Yakult Central Institute, Yakult Honsha Co., Ltd., 5-11 Izumi, Kunitachi-shi, Tokyo 186-8650, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"YAMAZAKI","sequence":"additional","affiliation":[{"name":"Yakult Central Institute, Yakult Honsha Co., Ltd., 5-11 Izumi, Kunitachi-shi, Tokyo 186-8650, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5076","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kahn BB, Flier JS. 2000. Obesity and insulin resistance. J Clin Invest 106: 473\u2013481.","DOI":"10.1172\/JCI10842"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Kahn SE, Hull RL, Utzschneider KM. 2006. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444: 840\u2013846.","DOI":"10.1038\/nature05482"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Engin A. 2017. The definition and prevalence of obesity and metabolic syndrome. Adv Exp Med Biol 960: 1\u201317.","DOI":"10.1007\/978-3-319-48382-5_1"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Han TS, Lean ME. 2016. A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. JRSM Cardiovasc Dis 5: 2048004016633371.","DOI":"10.1177\/2048004016633371"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Takeuchi T, Kameyama K, Miyauchi E, Nakanishi Y, Kanaya T, Fujii T, Kato T, Sasaki T, Tachibana N, Negishi H, et al. 2023. Fatty acid overproduction by gut commensal microbiota exacerbates obesity. Cell Metab 35: 361\u2013375.e9.","DOI":"10.1016\/j.cmet.2022.12.013"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Crudele L, Gadaleta RM, Cariello M, Moschetta A. 2023. Gut microbiota in the pathogenesis and therapeutic approaches of diabetes. EBioMedicine 97: 104821.","DOI":"10.1016\/j.ebiom.2023.104821"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Van Hul M, Cani PD. 2023. The gut microbiota in obesity and weight management: microbes as friends or foe? Nat Rev Endocrinol 19: 258\u2013271.","DOI":"10.1038\/s41574-022-00794-0"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Sarmiento-Andrade Y, Su\u00e1rez R, Quintero B, Garrochamba K, Chapela SP. 2022. Gut microbiota and obesity: new insights. Front Nutr 9: 1018212.","DOI":"10.3389\/fnut.2022.1018212"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. 2006. Microbial ecology: human gut microbes associated with obesity. Nature 444: 1022\u20131023.","DOI":"10.1038\/4441022a"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. 2006. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444: 1027\u20131031.","DOI":"10.1038\/nature05414"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hosomi K, Saito M, Park J, Murakami H, Shibata N, Ando M, Nagatake T, Konishi K, Ohno H, Tanisawa K, et al. 2022. Oral administration of Blautia wexlerae<\/i> ameliorates obesity and type 2 diabetes via metabolic remodeling of the gut microbiota. Nat Commun 13: 4477.","DOI":"10.1038\/s41467-022-32015-7"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Newman NK, Zhang Y, Padiadpu J, Miranda CL, Magana AA, Wong CP, Hioki KA, Pederson JW, Li Z, Gurung M, et al. 2023. Reducing gut microbiome-driven adipose tissue inflammation alleviates metabolic syndrome. Microbiome 11: 208.","DOI":"10.1186\/s40168-023-01637-4"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Le\u00f3n Aguilera XE, Manzano A, Pirela D, Berm\u00fadez V. 2022. Probiotics and gut microbiota in obesity: myths and realities of a new health revolution. J Pers Med 12: 1282.","DOI":"10.3390\/jpm12081282"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Cai Y, Liu P, Zhou X, Yuan J, Chen Q. 2023. Probiotics therapy show significant improvement in obesity and neurobehavioral disorders symptoms. Front Cell Infect Microbiol 13: 1178399.","DOI":"10.3389\/fcimb.2023.1178399"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. She J, Wong CC, Yu J. 2021. Targeted prebiotics alter the obese gut microbiome in humans. Signal Transduct Target Ther 6: 363.","DOI":"10.1038\/s41392-021-00758-2"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Megur A, Daliri EBM, Baltriukien\u0117 D, Burokas A. 2022. Prebiotics as a tool for the prevention and treatment of obesity and diabetes: classification and ability to modulate the gut microbiota. Int J Mol Sci 23: 6097.","DOI":"10.3390\/ijms23116097"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ocvirk S, O\u2019Keefe SJD. 2021. Dietary fat, bile acid metabolism and colorectal cancer. Semin Cancer Biol 73: 347\u2013355.","DOI":"10.1016\/j.semcancer.2020.10.003"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Wei M, Huang F, Zhao L, Zhang Y, Yang W, Wang S, Li M, Han X, Ge K, Qu C, et al. 2020. A dysregulated bile acid-gut microbiota axis contributes to obesity susceptibility. EBioMedicine 55: 102766.","DOI":"10.1016\/j.ebiom.2020.102766"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Rosendo-Silva D, Viana S, Carvalho E, Reis F, Matafome P. 2023. Are gut dysbiosis, barrier disruption, and endotoxemia related to adipose tissue dysfunction in metabolic disorders? Overview of the mechanisms involved. Intern Emerg Med 18: 1287\u20131302.","DOI":"10.1007\/s11739-023-03262-3"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Potrykus M, Szyma\u0144ski M, Kaska \u0141, Janczy A. 2022. Intestinal barrier disorders and metabolic endotoxemia in obesity: current knowledge. Postepy Hig Med Dosw 76: 71\u201380.","DOI":"10.2478\/ahem-2022-0008"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ghosh SS, Wang J, Yannie PJ, Ghosh S. 2020. Intestinal barrier dysfunction, LPS translocation, and disease development. J Endocr Soc 4: bvz039.","DOI":"10.1210\/jendso\/bvz039"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Ellulu MS, Patimah I, Khaza\u2019ai H, Rahmat A, Abed Y. 2017. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci 13: 851\u2013863.","DOI":"10.5114\/aoms.2016.58928"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Hotamisligil GS. 2006. Inflammation and metabolic disorders. Nature 444: 860\u2013867.","DOI":"10.1038\/nature05485"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Suganami T, Ogawa Y. 2010. Adipose tissue macrophages: their role in adipose tissue remodeling. J Leukoc Biol 88: 33\u201339.","DOI":"10.1189\/jlb.0210072"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Scheithauer TPM, Rampanelli E, Nieuwdorp M, Vallance BA, Verchere CB, van Raalte DH, Herrema H. 2020. Gut microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes. Front Immunol 11: 571731.","DOI":"10.3389\/fimmu.2020.571731"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Marseglia L, Manti S, D\u2019Angelo G, Nicotera A, Parisi E, Di Rosa G, Gitto E, Arrigo T. 2014. Oxidative stress in obesity: a critical component in human diseases. Int J Mol Sci 16: 378\u2013400.","DOI":"10.3390\/ijms16010378"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Rohr MW, Narasimhulu CA, Rudeski-Rohr TA, Parthasarathy S. 2020. Negative effects of a high-fat diet on intestinal permeability: a review. Adv Nutr 11: 77\u201391.","DOI":"10.1093\/advances\/nmz061"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Da Silva CC, Monteil MA, Davis EM. 2020. Overweight and obesity in children are associated with an abundance of Firmicutes and reduction of Bifidobacterium<\/i> in their gastrointestinal microbiota. Child Obes 16: 204\u2013210.","DOI":"10.1089\/chi.2019.0280"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Duan M, Wang Y, Zhang Q, Zou R, Guo M, Zheng H. 2021. Characteristics of gut microbiota in people with obesity. PLoS One 16: e0255446.","DOI":"10.1371\/journal.pone.0255446"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Xu Z, Jiang W, Huang W, Lin Y, Chan FKL, Ng SC. 2022. Gut microbiota in patients with obesity and metabolic disorders\u2014a systematic review. Genes Nutr 17: 2.","DOI":"10.1186\/s12263-021-00703-6"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Schellekens H, Torres-Fuentes C, van de Wouw M, Long-Smith CM, Mitchell A, Strain C, Berding K, Bastiaanssen TFS, Rea K, Golubeva AV, et al. 2021. Bifidobacterium longum<\/i> counters the effects of obesity: partial successful translation from rodent to human. EBioMedicine 63: 103176.","DOI":"10.1016\/j.ebiom.2020.103176"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Gong H, Gao H, Ren Q, He J. 2022. The abundance of bifidobacterium<\/i> in relation to visceral obesity and serum uric acid. Sci Rep 12: 13073.","DOI":"10.1038\/s41598-022-17417-3"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Kondo T, Kishi M, Fushimi T, Ugajin S, Kaga T. 2009. Vinegar intake reduces body weight, body fat mass, and serum triglyceride levels in obese Japanese subjects. Biosci Biotechnol Biochem 73: 1837\u20131843.","DOI":"10.1271\/bbb.90231"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Zhao L, Xie Q, Evivie SE, Yue Y, Yang H, Lv X, Liu F, Li B, Huo G. 2022. Bifidobacterium longum<\/i> subsp. Longum<\/i> K5 alleviates inflammatory response and prevents intestinal barrier injury induced by LPS in vitro<\/i> based on comparative genomics. J Funct Foods 92: 105030.","DOI":"10.1016\/j.jff.2022.105030"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Kim JY, Bang SJ, Kim JY, Choi EJ, Heo K, Shim JJ, Lee JL. 2022. The probiotic strain Bifidobacterium animalis<\/i> ssp. lactis HY8002 potentially improves the mucosal integrity of an altered intestinal microbial environment. Front Microbiol 13: 817591.","DOI":"10.3389\/fmicb.2022.817591"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Al-Sadi R, Dharmaprakash V, Nighot P, Guo S, Nighot M, Do T, Ma TY. 2021. Bifidobacterium bifidum<\/i> enhances the intestinal epithelial tight junction barrier and protects against intestinal inflammation by targeting the toll-like Receptor-2 pathway in an NF-\u03baB-independent manner. Int J Mol Sci 22: 8070.","DOI":"10.3390\/ijms22158070"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Hsieh CY, Osaka T, Moriyama E, Date Y, Kikuchi J, Tsuneda S. 2015. Strengthening of the intestinal epithelial tight junction by Bifidobacterium bifidum<\/i>. Physiol Rep 3: e12327.","DOI":"10.14814\/phy2.12327"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Wang X, Fukui H, Ran Y, Xu X, Ebisutani N, Nakanishi T, Tanaka Y, Maeda A, Makizaki Y, Tomita T, et al. 2021. Probiotic Bifidobacterium bifidum<\/i> G9-1 has a preventive effect on the acceleration of colonic permeability and M1 macrophage population in maternally separated rats. Biomedicines 9: 641.","DOI":"10.3390\/biomedicines9060641"},{"key":"39","doi-asserted-by":"publisher","unstructured":"39. Castro-Herrera VM, Rasmussen C, Wellejus A, Miles EA, Calder PC. 2020. In vitro<\/i> effects of live and heat-inactivated Bifidobacterium animalis<\/i> subsp. lactis, BB-12 and Lactobacillus rhamnosus<\/i> GG on Caco-2 cells. Nutrients 12: 1719.","DOI":"10.3390\/nu12061719"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Devriese S, Van den Bossche L, Van Welden S, Holvoet T, Pinheiro I, Hindryckx P, De Vos M, Laukens D. 2017. T84 monolayers are superior to Caco-2 as a model system of colonocytes. Histochem Cell Biol 148: 85\u201393.","DOI":"10.1007\/s00418-017-1539-7"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Guo S, Al-Sadi R, Said HM, Ma TY. 2013. Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro<\/i> and in vivo<\/i> by inducing enterocyte membrane expression and localization of TLR-4 and CD14. Am J Pathol 182: 375\u2013387.","DOI":"10.1016\/j.ajpath.2012.10.014"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Valdez JC, Bolling BW. 2019. Anthocyanins and intestinal barrier function: a review. J Food Bioact 5: 18\u201330.","DOI":"10.31665\/JFB.2019.5175"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Al-Sadi R, Guo S, Ye D, Rawat M, Ma TY. 2016. TNF-\u03b1 modulation of intestinal tight junction permeability is mediated by NIK\/IKK-\u03b1 axis activation of the canonical NF-\u03baB pathway. Am J Pathol 186: 1151\u20131165.","DOI":"10.1016\/j.ajpath.2015.12.016"},{"key":"44","doi-asserted-by":"crossref","first-page":"e25718","DOI":"10.4161\/tisb.25718","volume":"1","year":"2013","unstructured":"44. Rao RK, Samak G. 2013. Bile duct epithelial tight junctions and barrier function. Tissue Barriers 1: e25718.","journal-title":"Tissue Barriers","ISSN":"https:\/\/id.crossref.org\/issn\/2168-8362","issn-type":"print"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Nagara Y, Fujii D, Takada T, Sato-Yamazaki M, Odani T, Oishi K. 2022. Selective induction of human gut-associated acetogenic\/butyrogenic microbiota based on specific microbial colonization of indigestible starch granules. ISME J 16: 1502\u20131511.","DOI":"10.1038\/s41396-022-01196-w"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Abdulqadir R, Al-Sadi R, Haque M, Gupta Y, Rawat M, Ma TY. 2024. Bifidobacterium bifidum<\/i> strain BB1 inhibits tumor necrosis factor-\u03b1-induced increase in intestinal epithelial tight junction permeability via toll-like receptor-2\/toll-like receptor-6 receptor complex-dependent stimulation of peroxisome proliferator-activated receptor \u03b3 and suppression of NF-\u03baB p65. Am J Pathol 194: 1664\u20131683.","DOI":"10.1016\/j.ajpath.2024.05.012"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Yue Y, Wang Y, Xie Q, Lv X, Zhou L, Smith EE, Cao T, Zhang Y, Li B, Huo G, et al. 2023. Bifidobacterium bifidum<\/i> E3 combined with Bifidobacterium longum<\/i> subsp. infantis E4 improves LPS-induced intestinal injury by inhibiting the TLR4\/NF-\u03baB and MAPK signaling pathways in vivo<\/i>. J Agric Food Chem 71: 8915\u20138930.","DOI":"10.1021\/acs.jafc.3c00421"}],"container-title":["Bioscience of Microbiota, Food and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bmfh\/45\/4\/45_2026-022\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:27:20Z","timestamp":1791602840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bmfh\/45\/4\/45_2026-022\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.12938\/bmfh.2026-022","relation":{},"ISSN":["2186-3342"],"issn-type":[{"value":"2186-3342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"2026-022"}}